Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil
National Center for Advancing Translational Sciences
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil
Haley Hedlin, Stephen P. Luby, Di Lu, Patrícia Vieira da Silva et al.
Citations
1 citations
Journal
The Lancet Regional Health - Americas
Topics
SARS-CoV-2 and COVID-19 Research
Field-Weighted Citation Impact (FWCI)
1.40
article
Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil
Haley Hedlin, Stephen P. Luby, Di Lu, Patrícia Vieira da Silva, Vivek Charu, Roberto Dias de Oliveira, Jessica Couvillion Seidman, Amy Zhang, Marco Antonio Moreira Puga, Blake Shaw, Joelle I. Rosser, Denise O. Garrett, Júlio Croda, Farah Naz Qamar, Alice Carter
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet Regional Health - AmericasVol. 44
Institutions
Aga Khan University (PK), Universidade Federal de Mato Grosso do Sul (BR), European Union of Medical Specialists (BE), Universidade Federal da Grande Dourados (BR), Universidade Estadual de Mato Grosso do Sul (BR), Yale University (US), Stanford Medicine (US), Sabin Vaccine Institute (US), Fundação Oswaldo Cruz (BR), Stanford University (US)
Funders
Foundation for the National Institutes of Health, Sabin Vaccine Institute, Coalition for Epidemic Preparedness Innovations, National Institutes of Health, Stanford Bio-X, National Center for Research Resources, National Center for Advancing Translational Sciences